Loading...
XSTOVIMIAN
Market cap1.97bUSD
Dec 20, Last price  
42.10SEK
1D
2.06%
1Q
-2.21%
IPO
-52.16%
Name

Vimian Group AB

Chart & Performance

D1W1MN
XSTO:VIMIAN chart
P/E
192.43
P/S
5.71
EPS
0.02
Div Yield, %
0.00%
Shrs. gr., 5y
3.78%
Rev. gr., 5y
110.10%
Revenues
332m
+17.92%
8,103,00024,531,000137,752,000173,350,000281,308,000331,730,000
Net income
10m
P
-790,000-1,227,00052,794,0006,586,000-7,198,0009,840,000
CFO
-29m
L
-2,024,0001,548,0004,801,00016,014,00025,313,000-28,576,000
Earnings
Feb 13, 2025

Profile

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
IPO date
Jun 18, 2021
Employees
1,068
Domiciled in
SE
Incorporated in
SE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
331,730
17.92%
281,308
62.28%
173,350
25.84%
Cost of revenue
107,975
152,597
94,789
Unusual Expense (Income)
NOPBT
223,755
128,711
78,561
NOPBT Margin
67.45%
45.75%
45.32%
Operating Taxes
8,963
8,122
5,000
Tax Rate
4.01%
6.31%
6.36%
NOPAT
214,792
120,589
73,561
Net income
9,840
-236.70%
(7,198)
-209.29%
6,586
-87.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
443
139,627
51,262
BB yield
0.00%
-1.27%
-0.18%
Debt
Debt current
3,490
4,816
9,984
Long-term debt
322,043
229,986
180,062
Deferred revenue
97
Other long-term liabilities
61,770
35,259
21,413
Net debt
230,464
180,927
133,135
Cash flow
Cash from operating activities
(28,576)
25,313
16,014
CAPEX
(7,926)
(10,308)
(11,492)
Cash from investing activities
(77,677)
(188,533)
(114,997)
Cash from financing activities
100,545
150,229
123,941
FCF
158,956
122,749
50,269
Balance
Cash
37,500
42,194
55,114
Long term investments
57,569
11,681
1,797
Excess cash
78,482
39,810
48,244
Stockholders' equity
58,833
52,972
63,656
Invested Capital
843,449
689,724
504,398
ROIC
28.02%
20.20%
17.30%
ROCE
24.80%
17.07%
13.78%
EV
Common stock shares outstanding
453,497
403,114
349,977
Price
29.60
8.74%
27.22
-65.70%
79.35
 
Market cap
13,423,518
22.33%
10,972,766
-60.49%
27,770,635
 
EV
13,654,320
11,157,837
27,904,996
EBITDA
255,787
155,938
95,250
EV/EBITDA
53.38
71.55
292.97
Interest
19,255
11,052
6,717
Interest/NOPBT
8.61%
8.59%
8.55%